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Cancer stem cells (CSCs) are defined by their unlimited self-renewal ability 
and their capacity to initiate and maintain malignancy, traits that are not 
found in most cells that comprise the tumor.  Although current cancer 
treatments successfully reduce tumor burden, the tumor will likely recur 
unless CSCs are effectively eradicated.  This challenge is made greater by 
the protective impact of the tumor microenvironment (TME), consisting of 
infiltrating immune cells, endothelial cells, extracellular matrix, and signal-
ing molecules.  The TME acts as a therapeutic barrier through immunosup-
pressive, and thereby tumor-promoting, actions.  These factors, outside of 
the cancer cell lineage, work in concert to shelter CSCs from both the 
body’s intrinsic anticancer immunity and pharmaceutical interventions in 
order to maintain cancer growth.  Emerging therapies aimed at the TME 
offer a promising new tool in breaking through this shield to target the 
CSCs, yet definitive treatments remain unrealized.  In this review, we 
summarize the mechanisms by which CSCs are protected by the TME and 





Cancer stem cells differ from bulk tumor cells due to their ability to cre-
ate a heterogeneous tumor population, unlimited self-renewal, and prolifer-
ation.  The tumor microenvironment (TME) provides a shelter for these cells 
through the presence and actions of stroma, vasculature, extracellular ma-
trix, signaling molecules, and immune cells.  The TME has increasingly been 
recognized as an important component of therapy resistance and tumor 
progression.  Unlike tumor cells, the critical components that comprise the 
TME and their roles in tumor progression are common between different 
cancers.  A thorough understanding of cancer stem cell-TME interactions is 





Despite an enormous effort to cure cancer, the last 50 
years’ increase in long-term survival is primarily the 
result of behavioral changes (e.g. less cigarette smok-
ing) rather than the rational development of pharma-
ceuticals or biologics to target the cancer [1].  The un-
derlying explanation largely lies in our incomplete un-
derstanding of cancer biology. Two major break-
throughs in the last 20 years have fundamentally al-
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tered our view of cancer. First, we now recognize that 
cancer stem cells (CSCs) are the origin of many cancers.  
Second, the tumor microenvironment (TME) is a critical-
ly important protector of malignant cells, especially 
CSCs.  Thus, greater knowledge of both CSC biology in 
the TME and the impact of each TME component on 
cancer persistence may shed light on novel therapeutic 
approaches. Here, we review the current understanding 
of CSCs in the TME and briefly highlight potential inter-
ventional targets. 
 
Cancer Stem Cells 
Lapidot et al first identified cancer stem cells in acute 
myeloid leukemia using severe combined immune-
deficient mice [2].  Since then researchers have repli-
cated this finding in multiple blood and solid cancers, 
including chronic myelogenous leukemia [3], brain [4], 
breast [5], ovarian [6], head and neck [7], colon [8], liver 
[9], pancreas [10], and prostate cancers [11], suggesting 
that CSCS are a general characteristic of many cancers.  
Alternatively referred to as tumor-initiating or cancer 
stem-like cells, CSCs exhibit three defining characteris-
tics:  self-renewal, unlimited proliferation, and the abil-
ity to create a heterogeneous population [12].  This 
third trait is achieved (while maintaining stemness) 
through asymmetric division [13], similar to healthy 
tissue-specific adult stem cells.  For a more expansive 
discussion of the history and complexity of CSC re-
search, please see Kreso and Dick [14], Nassar and 
Blanpain [15], and Reya et al [16]. 
Two theories have emerged to explain the origin of 
cancer stem cells.  The stochastic model contends that 
cancer cells are intrinsically and biologically compara-
ble.  CSCs emerge as a result of environmental influ-
ences that alter the cell’s phenotype.  In this model, all 
cancer cells have the potential to emerge as CSCs based 
on environmental cues [16].  Conversely, the hierarchy 
model states that tumors consist of specific subsets of 
cells.  Only a small number of cells in any tumor have 
gained the mutations necessary for stemness, and dif-
ferentiation of these cells’ progeny results in all other 
tumor subsets [17].  Chaffer and Weinberg merged 
these models through the concept of cellular plasticity 
for describing solid tumors.  In this model, transit-
amplifying cells can de-differentiate into CSCs.  This 
bidirectional differentiation allows for a specific subset 
of tumor-initiating cells while also acknowledging the 
potential for differentiated cells to enter this pool if 
they undergo mutations in stem-like genes [18].  Such 
distinction is important, as a limited number of CSCs 
may be present within the tumor at any one time but 
this model predicts that any cancer cell could revert 
into a CSC under the right conditions. 
The CSC phenotype differs from the tumor bulk in 
critical ways.  While the majority of cancer cells exhibit 
limited proliferative capacity, CSCs maintain the ability 
to divide indefinitely but can reside in a comparatively 
more quiescent state [12]. Traditional cancer treat-
ments target actively dividing cells, including radiation 
and most chemotherapeutic agents.  These therapies 
therefore reduce tumor bulk as a whole but do not ef-
fectively kill CSCs, often leading to tumor recurrence.  
For example, breast CSCs demonstrate paclitaxel re-
sistance [19] and lower ROS expression, which are criti-
cal for ionizing radiation to induce DNA damage [20].  
Additionally, glioma CSCs upregulate checkpoint regula-
tors ATM, Rad17, and Chk1/2 after radiation, activating 
repair pathways that increase survival [21].  Together, 
aberrant ROS scavenging, DNA damage and DNA repair 
pathways have been reported in multiple CSC lineages 
[22].  Although progress has been made in using metro-
nomic chemotherapy regimens [23], the DNA damage 
responses in CSCs remain an obstacle to achieving 
chemotherapy-induced remission [24].  Additionally, 
even if CSCs are eradicated, other cancer cells have the 
potential to revert to CSCs and repopulate the tumor 
(according to the cellular plasticity model of CSCs) [18].  
This process is critically important in combating cancer 
recurrence.  Identifying and removing the factors that 
facilitate this de-differentiation remains a central chal-
lenge in cancer treatment. 
Current research has focused on developing drugs 
that target signaling pathways involved in stemness, 
including γ-secretase inhibitors, cancer stem cell vac-
cines, Wnt ligand modification/antagonist upregulation, 
and antibodies against CSC cell surface markers [25]. 
However, these therapies require understanding CSC 
biology, which may differ among cancers.  For example, 
therapies aimed at CD44+ CSCs, a common marker in 
cancers such as head and neck, breast, and colorectal 
cancers, may not effectively target CD133+ CSCs com-
mon to glioma and lung cancer [26].  Additionally, the 
tumor microenvironment impedes drug penetration 
into the tumor and suppresses the immune system’s 
activation against cancer cells [27].  Therefore, an ap-
proach that can circumvent these obstacles by modulat-
ing the tumor microenvironment and assaulting com-
mon tumor-supportive components would be a critical 
tool in cancer therapy.  Our ability to attain this goal is 
reliant on expanding knowledge of the microenviron-
ment’s role in cancer cell survival. 
 
Tumor Microenvironment 
The tumor microenvironment (TME) is composed of 
stroma, vasculature, extracellular matrix (ECM), signal-
ing molecules, and immune cells.  Increasingly, the TME 
has been recognized as an important component of 
therapy resistance and tumor progression. The tumor 
microenvironment is heterogeneous and dependent on 
location within the tumor, such that the TME at the 
tumor periphery may differ significantly from the TME 
within the tumor core [28].  These differences are in 
part due to immune cell infiltration, tumor cell necrosis, 
interstitial pressure, and randomly occurring mutations 
within the tumor cells [29].  Although each tumor builds 
its own unique TME, the critical components that com-
prise the TME and their roles in tumor progression are 
common between different cancers. 
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The TME offers a promising avenue for new cancer 
treatments because, in contrast to CSCs, stromal com-
ponents show relatively low mutation rate [12], making 
evasion of an effective therapeutic agent less likely.  
Unlike CSC therapy which may require specification for 
each cancer type [26], many of the TME protective 
mechanisms are shared across tumor types.  Therefore, 
the TME represents a broad set of factors common to 
many tumors that influence tumor development, posing 
an attractive target for therapy development.  Below, 
each component of the TME and its contribution to 
cancer persistence is examined. 
Extracellular Matrix:  Tumor cells are embedded 
within a dense ECM composed of collagen, glycopro-
tein, proteoglycans, polysaccharides, and proteins [30], 
which differs from normal ECM by its density and mo-
lecular composition.  Increased matrix deposition and 
fibrosis (desmoplasia) physically prevents treatments 
such as chemotherapy, biologics, and other pharmaceu-
ticals from direct contact with tumor cells [31].  Hyalu-
ronan and collagen increase tension in the ECM.  This 
leads to growth-induced solid stress, in which cancer 
cell proliferation is confined by ECM rigidity and puts 
pressure on blood vessels, leading to hypoxia and de-
creased perfusion of systemic drug therapy [32]. 
ECM also promotes tumor growth by growth factor 
and cytokine sequestration.  When the ECM is cleaved 
by pericellular proteases such as matrix metalloprote-
ases (MMPs) [33], molecules such as E-cadherin and 
pro-hepatocyte growth factor are released into the TME 
to stimulate cell survival and migration [34].  The ECM 
also has direct effect on CSCs through molecules such as 
MMP-3, which binds the Wnt ligand Wnt5b and causes 
expansion of mammary epithelial stem cells and hyper-
plasia [35].  Similarly, MMP-14 degrades collagen, re-
models the ECM, and releases heparin binding-
epidermal growth factor to activate EGFR pathway, 
leading to lung cancer growth [36].  Thus, the ECM 
physically protects CSCs from treatment and provides a 
repository of pro-tumorigenic cytokines. 
Angiogenesis:  Tumoral angiogenesis, in which endo-
thelial cells and associated pericytes sprout new blood 
vessels from existing ones and extend into the tumor 
[37], occurs rapidly but  is disorganized, with decreased 
pericyte coverage, weak pericyte adhesion to the endo-
thelium, and convoluted blood flow [38].  Rapid cellular 
proliferation combined with high oxygen consumption 
rate in cancer causes inadequate nutrient delivery to 
the tumor, resulting in compressed blood vessels and 
hypoxia.  Hypoxia activates HIF1α in tumor cells, a tran-
scription factor that positively regulates alternative an-
giogenic signaling such as PIGF, bFGF, and PDGF path-
ways [39] and stimulates aerobic glycolysis, both of 
which correlate with poor patient prognosis and metas-
tasis [40].  Vascular leakiness also allows hormones and 
other locally secreted factors to diffuse through the 
tumor with little resistance [41].  Pro-tumorigenic im-
mune cells within the tumor mass (described herein) 
can thus locally secrete immune-suppressive cytokines 
such as IL-10, IL-17A, and TGF-β that bathe the tumor 
despite inadequate vascular networks which systemical-
ly delivered drugs are unable to penetrate [42]. 
Angiogenesis is directly impacted by CSCs through 
signaling between CSCs and angiogenic endothelial cells 
in several cancers, including brain [43], breast [44], and 
liver [45] malignancies.  CSCs that release angiogenic 
factors into the TME to promote vascularization include 
HCC progenitor cells [45], VEGF, SDF-1, and HIF expres-
sion in glioma stem cells [43],  and VEGF, PDGF, and 
Ang-1 in breast CSCs [44].  By promoting angiogenesis, 
CSCs promote tumor progression through increased 
nutrient delivery. 
Metabolism:  Insufficient blood flow to the tumor 
due to disorganized angiogenesis creates a unique and 
demanding metabolic environment.  Concentrations of 
energy sources are commonly lower in the tumor com-
pared to normal tissues, forcing the cancer cells to 
switch to glycolysis in order to survive [46].  Activated 
immune cells also rely on glycolysis for energy, to pro-
liferate, and to carry out effector functions (ex: IFN-γ 
release and mTOR activity [47]), creating competition 
between the two populations. 
In the model proposed by Kareva and Berezovskaya, 
cancer cells in the solid tumor core rely primarily on 
glycolysis, while tumor cells at the periphery are able to 
perform aerobic metabolism.  T cells (described herein) 
and glycolytic cancer cells upregulate expression of glu-
cose transporters such as GLUT-1 and SGLT-1 to in-
crease uptake [48].  Activated T cells are able to uptake 
glucose at the tumor periphery without significant 
competition from aerobic tumor cells.  However, once 
the T cells penetrate the tumor core or eradicate pe-
ripheral tumor cells to expose glycolytic cells within the 
tumor, T cells must compete with cancer cells for the 
available glucose.  Tumors that are able to out-compete 
immune cells thus may grow in the absence of function-
ing T cells [48]. 
CSCs in solid tumors surround themselves with non-
stem cancer cells (their progeny) which engage in this 
resource competition, thus protecting the CSCs from T 
cell targeting.  This may contribute to the observation 
that CSCs are most frequently found within hypoxic 
regions of the tumor where glycolysis is prevalent [49].  
Metronomic chemotherapy is designed to target this 
CSC defense by using smaller doses of chemotherapy 
administered frequently but not continuously, allowing 
layers of the tumor to be removed sequentially [49].  
This treatment schedule was found to be more effective 
in treating mouse pancreatic adenocarcinoma [50], 
melanoma [51], and triple-negative breast cancer [52] 
as compared to standard chemotherapy and anti-
angiogenic therapy, suggesting that the immune cells 
are able to attack CSCs as they are revealed without 
reaching T cell exhaustion [49]. 
Interestingly, Chang et al observed that differences 
in glucose uptake between tumor cells do not necessari-
ly correlate with proliferation, suggesting that tumors 
may select for rapid glucose uptake based on the im-
TME protects cancer stem cells 
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munosuppressive effects [47].  In addition to out-
competing immune cells for glucose, cancer cells acidify 
their environment through glycolysis.  Low pH impedes 
HIF1α degradation, which increases angiogenesis and 
VEGF signaling.  This in turn increases the local myeloid-
derived suppressor cell population which secretes im-
munosuppressive signaling molecules, such as nitric 
oxide and reactive oxygen species, or differentiates into 
tumor-associated macrophages (described herein) 
which support tumor growth [53].  While much remains 
unknown about the mechanisms through which tumors 
evade the immune system, there is much to suggest 
that manipulating cancer cell metabolism may provide 
multiple benefits that permit greater immune activation 
against the tumor. 
Mesenchymal stem/stromal cells:  Defined by their 
ability to differentiate into multiple stromal cell line-
ages, MSCs are found throughout the body and traffic 
to specific tissues, including tumors, in the context of 
remodeling [54].  Tumors are considered “wounds that 
do not heal” due to chronic inflammation, neovasculari-
zation, and immune cell infiltration [55].  Growth fac-
tors secreted into this environment such as IL-10, VEGF, 
and GM-CSF facilitate MSC collection.  This phenome-
non, which in turn reduces antitumor T cell activity by 
MSC release of TGF-β into the TME, has been observed 
in metastatic melanoma, head and neck, prostate, and 
breast cancers [56,57]. 
MSCs act directly and indirectly on cancer stem cells 
to increase chemoresistance.  Roodhart et al showed 
that MSCs contribute to tumor progression by secreting 
fatty acids that increase chemoresistance in colon car-
cinoma [58].  In acute lymphoblastic leukemia, MSCs 
secrete chemoattractants and pro-survival growth fac-
tors in response to tyrosine kinase inhibitor treatment, 
which facilitate cancer cell chemoresistance [59].  Simi-
larly, exosomes (small extracellular vesicles released 
from cells upon fusion of an intermediate endocytic 
compartment with the plasma membrane [60]) derived 
from MSCs increased 5-fluorouracil resistance ex vivo 
and in vivo in gastric cancer animal models [61].  Cuiffo 
et al demonstrated that cell-cell contact between breast 
cancer cells and MSCs increased CSC properties through 
miRNA upregulation [56].  Together, these findings 
demonstrate that MSCs support tumor progression 
through many varied mechanisms, some likely not yet 
described. 
Fibroblasts:  When activated by direct contact with 
leukocytes or secreted factors such as TGF-β, PDGF, and 
GM-CSF [62], cancer-associated fibroblasts (CAFs) pro-
mote tumor growth, increase angiogenesis, degrade 
ECM to release embedded signaling molecules, and 
promote epithelial to mesenchymal transition (EMT) 
and metastasis [63].  CAFs are derived from MSCs, nor-
mal fibroblasts, or epithelial cells.  They highly express 
surface markers such as α-smooth muscle actin (αSMA), 
fibroblast activation protein (FAP), Thy-1, and S100A4 
protein [64].  CAFs are defined functionally by their high 
division rate and high ECM deposition, and have been 
described as “activated myofibroblasts that cannot re-
gress to the inactivated state” [65]. 
CAFs are enriched in human tumors following 
chemotherapy [66], which leads to increased CSC regu-
lation through paracrine signaling.  Erez et al [67] 
showed that CAFs from early neoplastic murine skin 
lesions exhibit a distinctive inflammatory gene signa-
ture, including IL-6, IL-1β, and CXCL2, a finding that was 
replicated in human squamous cell carcinoma.  Tumor 
cells co-injected with CAFs grew faster and were more 
vascularized than tumor cells injected alone [67].  Simi-
larly, CAF inflammatory mediators increased metastasis 
in hepatocellular carcinoma [68].  CAFs in non-small-cell 
lung cancer were found to trigger IGF1R pathway in 
cancer cells, leading to increased stemness marker 
Nanog expression and greater level of sphere formation 
in vitro and metastasis in vivo [69].  In hepatocellular 
carcinoma, CAFs secrete HGF to increase tumor cell self-
renewal capacity [70].  CAFs have also been shown to 
contribute to stemness in glioblastoma, leukemia, and 
gastric cancer through secretion of TGF-β, STAT1 and 
NF-κB [66,71].  Because of their role in tumor progres-
sion, CAFs may prove a valuable target in transforming 
the TME towards tumor suppression. 
 
Immune Modulation 
The immune system is tightly regulated to protect the 
body, but dysregulation paradoxically contributes to 
tumor progression and invasion.  Rather than inhibiting 
tumor growth and progression, the immune system is 
co-opted to protect the tumor against the body.  The 
tumor actively regulates the TME to protect itself from 
clearance by infiltrating immune cells, including Treg, 
macrophages, dendritic, natural killer, T, and B cells 
[27,72].  Tumor evasion also occurs through prolonged 
cancer cell-mediated NF-κB activation and signaling, 
which has been demonstrated to drive immune inhibi-
tion and tumor progression in lung, breast, and prostate 
cancers [57,73].  By re-directing the immune system to 
recognize and attack tumor cells, immunotherapies 
have the potential to create lasting remission.  These 
approaches can be divided into innate and adaptive 
immune modulators; here we focus on a selection of 
key components. 
Innate Immunity:  Innate immune activation is rapid 
and can target a broad range of stimuli, but chronic 
inflammation has been linked to tumor progression and 
angiogenesis through a persistent wound-like state [62].  
As important members of the innate immune system, 
natural killer (NK) cells and macrophages are appealing 
targets for investigators working to tip the balance of 
the TME towards tumor eradication. 
When activated, NK cells either release granzymes 
and perforin to permeabilize target cells or activate the 
death receptor (FAS, TRAIL) pathways, resulting in 
apoptosis [74].  In addition to their own cytotoxic activi-
ty, NK cells magnify the immune response by releasing 
interferon-γ, which in turn promotes the Th1 (pro-
inflammatory helper T cell) immune response, increases 
TME protects cancer stem cells 
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antigen-presenting cell activity, activates macrophages, 
and reduces neoplastic cell proliferation [75].  NK cells 
simultaneously receive activating and inhibitory signals, 
the balance of which determines the cells’ function [75]. 
Recent work has highlighted the importance of NK 
cells in targeting CSCs.  Using freshly isolated patient 
samples from breast cancers, sarcomas, and pancreatic 
cancers, Grossenbacher et al demonstrated that CSCs 
upregulate stress ligands in response to radiation ther-
apy, which are then preferentially targeted by NK cell 
immunotherapy [76].  A similar preference for CSCs by 
NK cells was revealed in colon cancer, melanoma, and 
glioblastoma [77].  In bladder cancer, chemoresistant 
CSCs treated with activated-NK cell supernatants 
demonstrated decreased stemness (as measured by 
ALDH activity and mRNA panel for stem markers) and 
increased cisplatin sensitivity [78].  Together, these 
findings reveal that NK cells can target and kill CSCs if 
they are able to penetrate the tumor and overcome the 
tumor’s defense mechanisms. 
Tumor cells deploy multiple mechanisms to evade 
NK-mediated immune killing.  Tumors that either re-
lease the cytotoxic lymphocyte-activating molecule 
NKG2DL into circulation or downregulate its expression 
on tumor cells, as occurs in melanoma, hepatic carci-
noma, breast, and hematologic cancers, block effective 
NK cell-mediated tumor targeting [74,79].  Certain can-
cers, such as leukemia, upregulate MHC class 1 or HLA-
G expression to inhibit NK cell activation [80].  Limited 
infiltration into solid tumors also limits NK cytotoxic 
ability [81].  NK cell-based immunotherapy aims to 
overcome these obstacles by (1) facilitating NK infiltra-
tion into the tumor, (2) increasing NK activation inside 
the tumor, and (3) enhancing NK-mediated cytotoxicity 
[82]. 
Like NK cells, macrophages are one of the body’s 
first-line defenses against foreign invaders.  Traditional-
ly, macrophages were thought to terminally differenti-
ate from monocytes into either the M1 macrophage 
phenotype, characterized by cytotoxic anti-tumor activi-
ty and type 1 interferon responses, or the M2 pheno-
type, which supports the tumor via immunosuppression 
and growth factor-mediated angiogenesis [83].  Howev-
er, continued research has shown that macrophages 
can switch between activation states throughout their 
lifespan [28,84,85], with conversion from M1 to M2 
mediated by growth factors such as TGF-β [42].  These 
two activation states represent two extremes of the 
spectrum.   Each individual cell exists along a continuum 
between the two poles, and its placement along that 
continuum can change in response to stimuli. 
Once a macrophage enters the tumor it becomes a 
tumor-associated macrophage (TAM), which typically 
resembles the M2 phenotype and differs from circulat-
ing macrophages in critical ways [62].  TAMs are re-
cruited by the tumor-derived chemokine CCL2 and mol-
ecules such as VEGF, PDGF, and TGF-β.  They then pro-
duce these growth factors themselves in an amplifica-
tion loop which contributes to angiogenesis and survival 
[42].  TAM-mediated tumor support occurs through:  
pro-tumorigenic growth factor release, angiogenic 
stimulation, tissue remodeling, ECM enzymatic cleav-
age, and reduction of adaptive immune responses such 
as inflammation and T cell maturation [86].  In relation 
to CSCs, TAMs have been shown to contribute to 
chemoresistance by releasing MFG-E8 protein to reduce 
cisplatin toxicity (lung and colon cancer) and by reduc-
ing CSC tumor initiation and STAT3 activation (pancreat-
ic cancer) [87].  Together, these functions demonstrate 
how cancer co-opts macrophages to support tumor 
progression and therapy resistance.  Recent studies in 
HCC, fibrosarcoma, melanoma, glioma, pancreatic, and 
breast cancers have shown that it is possible to repro-
gram TAMs to their tumor-destructive counterparts, 
and such reprogramming results in reduced angiogene-
sis and vascular normalization [38,88].  These findings 
support further research into the mechanisms of TAM-
mediated tumor progression and methods to reverse 
their effects. 
Adaptive Immunity:  Long-term cancer antigen im-
munity represents the “Holy Grail” in cancer immuno-
therapy, as it would mean the body has developed life-
long, effective immune surveillance precluding tumor 
recurrence.  However, this goal remains elusive due to 
complex immune evasion such as immunoediting, 
where immunogenic cancer cells are killed while non-
immunogenic cells proliferate [88].  As cancer muta-
tions arise over time, the immune system keeps tumor 
development in check until the non-immunogenic cells 
can escape and form a tumor mass.  By selecting for 
cells that evade it, the immune system thus creates an 
enemy equipped with the very tools needed to defeat it 
[89].  In this section, we will focus on T cells to illustrate 
these challenges. 
Like macrophages, the role of T cells as either pro- 
or anti-tumorigenic is largely dependent on environ-
mental stimulation [42].  For a full review of T cell sub-
types, see Hanahan and Coussens [38], Palucka and 
Coussens [90], Chen and Flies [91].  Inflammatory T cell 
cytokine secretion, most importantly IFN-γ, suppresses 
tumor development such that increased T cell infiltra-
tion in solid tumors correlates with better prognosis 
[92].  This effect is abrogated by the presence of immu-
nosuppressive T cells, such as CD4+ Th2, Th17 [62], and 
regulatory T cells (TReg), which suppress enrichment of 
other types of T cells in the tumor through both direct 
contact and by secreting TGF-β and IL-10 [57].  TReg are 
physiologically important because they block the im-
mune system from recognizing self-antigens; cancer co-
opts this mechanism, allowing the tumor to develop 
without T cell attack of cancer-associated neoantigens 
[38]. 
Also like macrophages, T cells can interconvert be-
tween phenotypes based on exposure to stimuli [93].  
CD4+ Th17 and Th2 cells can switch from producing IL-
17 to IFN-γ through a combination of metabolic, epige-
netic, and cytokine signaling pathways [94].  Memory 
TReg (CD4+ Foxp3+ CD25high CD27+ CD45RA−) can shift 
TME protects cancer stem cells 
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to a Th17-like phenotype in humans, expressing IL-17 
and CCR6 [95]. By inducing TReg to the Th17 phenotype 
through increased IL-6 production in dendritic cells, 
mice with B16 melanoma tumors demonstrated in-
creased antitumor activation [96].  A subset of TReg in 
highly inflammatory cancers such as colorectal carci-
noma and breast cancer produce adenosine or prosta-
glandin E2 to reduce inflammation and tumor develop-
ment, in contrast to the typical tumor-supportive role of 
TReg [97].  T cell plasticity has also been found in graft 
versus host disease [98], atherosclerosis [99], and in-
flammatory skin diseases [100], indicating the potential 
for a common pathway across diseases. 
Tumors have developed multiple mechanisms to cir-
cumvent cytotoxic T cell activity and amplify TReg signal-
ing.  While T cells primed against tumor antigens may 
exist in patients, they are blocked from attacking the 
tumor either physically by the ECM [101] or through 
immune suppression.  The ECM physically impedes T 
cell accumulation within the tumor, inhibiting antigen 
recognition [88].  Tumor evasion occurs via manipula-
tion of the Fas ligand (FasL), programmed cell death 
protein 1 (PD1), and cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4) pathways.  FasL, expressed in solid 
tumor vascular networks, induces apoptosis in bound 
cells, including T cells.  Tumors with high FasL expres-
sion show low cytotoxic T cell infiltration but high TReg 
activity due to high TReg expression of c-FLIP, an apopto-
sis inhibitor [88].  PD1/PDL1 interaction between tumor 
ligand and T cell receptor causes T cell inhibi-
tion/apoptosis and tumor proliferation [102], but para-
doxically PD1 activation on TReg produces increased im-
munosuppressive activity [103].  Long-term T cell expo-
sure to tumor antigens leads to high PD1 receptor ex-
pression and eventually T cell exhaustion.  Evasive 
measures also include increased PD1 expression on tu-
mor cells after exposure to IFN-γ released by invading 
leukocytes [89].  Like PD1, CTLA-4 negatively regulates T 
cell checkpoint progression [88]. 
The importance of the TME in T cell activation is evi-
dent in results from chimeric antigen receptor- T cell 
(CAR-T) therapy, in which T cells are genetically modi-
fied ex vivo to recognize tumor-associated antigens.  
Subsequently, infused T cells will be activated upon 
tumor antigen binding and kill target cells in vivo [102].  
CAR-T therapy has shown considerable success in treat-
ing leukemias but has shown limited efficacy in solid 
tumors [102], with the exception of promising data 
coming from studies of CAR-T therapy in neuroblastoma 
[104] and sarcoma [105].  The readily evident difference 
between solid and liquid tumors is the separation be-
tween CSCs protected in the TME away from the bulk of 
malignant cells in blood cancers versus the unity of 
these elements in solid tumors.  Therefore, the ob-
served difference in efficacy supports the assertion that 
the TME blocks immune-mediated tumor clearance 
[81].  If investigators are able to improve immune cell 
penetration and remove the TME barriers to immune 
clearance, then therapies such as CAR-T may be more 
effective in solid tumors, reaching the levels seen in 




The TME provides shelter for tumor cells, and espe-
cially CSCs, through regulation of the stroma, vascula-
ture, extracellular matrix, signaling molecules, and im-
mune cells.  Cancer has evolved to out-maneuver the 
body’s natural defenses against aberrant growth, and 
without targeting these defenses cancer is likely to re-
cur.  Additionally, even if the entire current comple-
ment of immune-evasive measures are successfully tar-
geted by new treatments, new, as-of-yet unknown 
mechanisms are likely to arise to counteract therapeutic 
efforts; hence, a continuously evolving, comprehensive 
understanding of TME biology is important to prepare 
ourselves for the future. Breakthroughs in basic biology 
will undoubtedly lead to both strategies for outpacing 
tumor evolution, which aims to evade pharmacologic 
and biologic therapies, and to more effective approach-
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Figure 1. The Tumor Microenvironment.  Tumor cells are embedded in a complex microenvironment served by tor-
tuous, disorganized blood vessels and composed of immune cells, ECM, fibroblasts, and MSCs.  (A) MSCs traffic into 
the tumor in response to cancer cell secretion of cytokines such as IL-10, VEGF, and GM-CSF.  Once inside the tumor, 
MSCs release exosomes and fatty acids into the TME.  This results in increased chemoresistance.  MSCs also decrease 
anti-tumor T cell activity.  (B) Cytotoxic T cells release IFN-γ, which suppresses tumor development.  Treg suppress in-
flammatory T cells through TGF-β, IL-10, or through direct contact.  T cells can interconvert between cytotoxic and 
regulatory T cell phenotypes. FasL, PDL1, and CTLA-4 upregulation on tumor cells blocks cytotoxic T cell activity but 
increases Treg immunosuppressive activity.  (C) Macrophages exhibit phenotypes along a spectrum between tumor-
suppressive M1 and tumor-supportive M2.  M1 mediate tumor cell apoptosis through IFN-γ and can convert to M2 
through factors such as tumor-secreted TGF-β.  M2 macrophages play many roles, including: ECM cleavage, tissue 
remodeling, angiogenesis, chemoresistance, and TAM recruitment.  (D) Tumor cell release of NKG2DL and upregula-
tion of MHC I and HLA-G suppresses NK cell activation.  Activated NK cells release granzymes and perforin to induce 
Fas and TRAIL-mediated apoptosis in cancer cells.  IFN-γ released by NK cells triggers a Th1 immune response, de-
creased tumor cell proliferation, and increased M1 activation. 
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Cancer stem cells (CSCs) are embedded within a complex tumor microenvironment with many components exerting 
influence over the CSCs.  The extracellular matrix (ECM), mesenchymal stem/stromal cells (MSCs), and certain sub-
types of T cells and macrophages promote CSC growth.  Natural killer (NK) cells and other subtypes of T cells and 
macrophages inhibit CSC proliferation. 
 
 
